Abstract
Alzheimer’s Disease (AD), or senile dementia of the Alzheimer type (SDAT), is an age-related neurodegenerative disorder characterized by a progressive deterioration of cognitive function with impairments in language, visuospatial ability and memory. The total number of individuals suffering from AD is rapidly rising as the percentage of elderly in the population increases with time. At the present, about 4 million Americans are afflicted with AD (for reviews, see Moos et al., 1988).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bartus RT, Dean RL, Beer B and Lippa AS (1982): The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408–416.
Christie JE, Shering A, Ferguson J and Glen AI (1981): Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46–50.
Fisher A, Brandeis R, Karton I, Pittel Z, Sapir M, Dachir S, Levy A and Heldman E (1988): AF-102B — a new Ml agonist as a rational treatment strategy in Alzheimer’s disease (AD). Amer Chem Soc Abst MEDI 67.
Harbaugh, RE, Roberts DW, Coombs DW, Saunders RL and Reeder TM (1984): Preliminary reports: intracranial cholinergic drug infusion in patients with Alzheimer’s disease. Neurosurgery 15:514–518.
Hobbs SH, Johnson SJ, Kesten SR, Pavia MR, Davis RE, Schwarz RD, Coughenour LL, Myers SL, Dudley DT and Moos WH (1991): Cholinergic agents: 2-oxalidinone analogues of the acetylcholine receptor muscarinic agonist pilocarpine. Bioorg Med Chem Lett (In Press).
Moos WH, Davis RE, Schwarz RD and Gamzu ER (1988): Cognition activators. Med Res Rev 8:353–391.
Nilsson BM, Ringdahl B and Hackseil U (1988): Derivatives of the muscarinic agent N-methyl-N(l-methyl-4-pyrolidino-2-butynyl) acet-amide. J Med Chem 31:577–582.
Pavia MR, Davis RE and Schwarz RD (1990): Cognition enhancers. Ann Rep Med Chem 25:21–29.
Perry RH (1986): Recent advances in neuropathology. Br Med Bull 42:34–41.
Saunders J and Freedman SB (1989): The design of full agonists for the cortical muscarinic receptor. TIPS 10(Suppl):70–75.
Tariot PN, Cohen RM, Welkowitz JA, Sunderland T, Newhouse PA, Murphy DL and Weingartner H (1988): Multiple-dose arecoline infusions in Alzheimer’s disease. Arch Gen Psychiatry 45:901–905.
Tecle H, Bergmeier S, Moos W, Hershenson F, Coughenour L, Davis R, Schwarz R, Moreland D and Dudley D (1989): Cholinergic agents: Tetrahydropyridine ketoximes spanning a range of muscarinic agonist and antagonist properties. Amer Chem Soc Abst MEDI 47.
Wanibuchi F, Usuda S, Konishi T, Harada M, Terai M, Hidoka K, Tsukamoto S and Tamura T. (1989): Characterization of novel agonists, 1-0xa-8-azaspiro [4,5], decane derivatives in biochemical and behavioral studies. Soc. Neurosci Abst 15:295.3.
Wettstein A and Spiegel R (1984): Clinical trials with the cholinergic drug RS-86 in Alzheimer’s disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology 845:572–573.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Schwarz, R.D. et al. (1991). Novel Muscarinic Agonists for the Treatment of Alzheimer’s Disease. In: Becker, R., Giacobini, E. (eds) Cholinergic Basis for Alzheimer Therapy. Advances in Alzheimer Disease Therapy. Birkhäuser, Boston, MA. https://doi.org/10.1007/978-1-4899-6738-1_37
Download citation
DOI: https://doi.org/10.1007/978-1-4899-6738-1_37
Publisher Name: Birkhäuser, Boston, MA
Print ISBN: 978-1-4899-6740-4
Online ISBN: 978-1-4899-6738-1
eBook Packages: Springer Book Archive